Nanna’s recent hiring activities completed! CAMBRIDGE (UK), November 10, 2022 – Nanna Therapeutics has attracted a raft of new talent. Meet the newest members of the team: New Head of Biology and Head of Chemistry “I am delighted to welcome Keith Moore as head of biology and Steve Penrose as head of chemistry to Nanna […]
We are expanding our talented team. Take a look at our open positions in our Careers section: Head of Medicinal Chemistry Head of Pharmacology Applicants must submit a CV and covering letter by email to jobs@nannatherapeutics.com Applicants are encouraged to apply as soon as possible as we will be reviewing applicants and interviewing on a […]
– Nanna’s unique screening platform has great potential to create novel programs, leading to maximization of mitochondria-related research TOKYO and CAMBRIDGE (UK), April 21, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Nanna Therapeutics Limited (CEO: David Williams, Ph.D., “Nanna”) today announced that Astellas has acquired Nanna, a […]
Nanna Therapeutics Awarded £829,892 Innovate UK Grant to Discover Novel Drugs Leveraging its Nanoscale Medicines Discovery Engine Expands Scientific Advisory Board with Appointment of Prof. David Spring Cambridge, UK, 9th April 2019 – Nanna Therapeutics Ltd, a biotechnology company developing novel drugs to combat age-related diseases, particular those caused by mitochondrial dysfunction, today announced that […]
Cambridge, UK, 14th August 2018 – Bactevo Ltd. announced today that Professor Pietro Lio of the Computer Laboratory in Cambridge University has joined its Scientific Advisory Board. Pietro brings a wealth of skills from the disciplines of bioinformatics and machine learning. During his distinguished career, Pietro has pioneered the development and testing of novel methodologies […]
Cambridge UK, 2nd May 2018 – Bactevo Ltd. announced today that it has entered into a drug discovery collaboration agreement with Boehringer Ingelheim to identify novel small molecule lead compounds. This collaboration leverages Bactevo’s revolutionary TIME (Totally Integrated Medicines Engine) platform, incorporating its ground-breaking synthetic chemistry technology, designed specifically to combine medicinally-relevant ‘tagless’ chemical diversity […]
Cambridge UK, 9th August 2017 – Bactevo’s Totally Integrated Medicines Engine (TIME) technology has been featured in the latest issue of Genetic Engineering & Biotechnology News (GEN). Click here to read the article. About Bactevo Bactevo has built a unique and game-changing Totally Integrated Medicines Engine (TIME) to create novel therapeutics. Utilising its paradigm shift in the speed, efficiency […]
Achieves 100 Million Disease-Relevant Assays per Hour Incorporates Ground-Breaking Synthetic Chemistry Platform Management Team and SAB Expanded to Accelerate Next Phase of Growth 25th April, 2017 CAMBRIDGE, UK – Bactevo Ltd today unveiled a game-changing Totally Integrated Medicines Engine (TIME) capable of 100 million phenotypic assays per hour, a landmark in disease-relevant assay screening. TIME […]
Cambridge UK, 25th January 2017 – Bactevo, the revolutionary Cambridge, UK-based drug discovery company has received an Innovate Award for a prestigious £1.5M grant. Exploiting revolutionary work in the field of integrated, accelerated drug discovery in micro-droplets, Bactevo will progress its programmes focused on generating new antibiotic drugs to highly drug resistant Gram-negative pathogens causing septicaemia, chest […]
Bactevo are delighted to announce the date of September 28th, 2017 for the second ChemBioSphere meeting (entitled ChemBioSphere: Reprogramming Drug Discovery), following the enormous success of the inaugural meeting last week. Four one-day meetings will be held in successive years aimed at bringing together experts, change makers and decision leaders from every part of the […]